Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers

Acta Oncologica

Volumn 51, Issue 2, 2012, Pages 234-242

  Rohrberg, Kristoffer S ^a   Olesen, René K ^b   Pfeiffer, Per ^c   Ladekarl, Morten ^b   Pappot, Helle ^a   Christensen, Ib J ^a   Høyer Hansen, Gunilla ^a   Sørensen, Morten ^a   Skov, Birgit G ^d   Buysschaert, Ian ^e,f   Carmeliet, Peter ^e,f   Lassen, Ulrik ^a  

^a FINSEN LABORATORY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; LOW MOLECULAR WEIGHT HEPARIN; OXALIPLATIN; UROKINASE RECEPTOR; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; BILE DUCT CANCER; BILIARY TRACT CANCER; CANCER RESISTANCE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG TARGETING; DRUG TOLERANCE; ESOPHAGUS CANCER; FATIGUE; FEMALE; HUMAN; HYPERTENSION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OVERALL RESPONSE RATE; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; SIDE EFFECT; SKIN MANIFESTATION; STOMACH CANCER; TREATMENT RESPONSE; UPPER GASTROINTESTINAL CANCER; UPPER GASTROINTESTINAL TRACT CANCER; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84856462139     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.619568     Document Type: Article

References (37)

1. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960 - 6.
2. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and metaanalysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-72.
3. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and effi cacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009;6:352-66.
4. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6.
5. Grothey A, Galanis E. Targeting angiogenesis: Progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18.
6. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009;15:3484-94.
7. Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: Rationale, preclinical studies and clinical applications. Nat Clin Prac Oncol 2008;5:521-30.
8. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, et al. Identifi cation of genotypecorrelated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profi ling. Proc Natl Acad Sci USA 2007;104:19936-41.
9. Piironen T, Laursen B, Pass J, List K, Gardsvoll H, Ploug M, et al. Specifi c immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 2004; 50:2059-68.
10. Rohrberg KS, Skov BG, Lassen U, Christensen IJ, Hoyer- Hansen G, Buysschaert I, et al. Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer. Cancer Biomark 2010;7:141-51.
11. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-7.
12. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-55.
13. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, et al. Phase II study of effi cacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-50.
14. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-50
15. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: A phase I/II study. Lancet Oncol 2009;10: 247-57.
16. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network. J Clin Oncol 2007;25:1747-52.
17. Larsen FO, Pfeiffer P, Nielsen D, Skougaard K, Qvortrup C, Vistisen K, et al. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer. Acta Oncol 2011;50:574-7.
18. Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113:808-14.
19. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536-41.
20. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, et al. Effi cacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008;110:49-55.
21. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, et al. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res 2008;14:7878-83.
22. Dingemans AM, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, Scholtens HT, et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: A phase II study including molecular imaging. Ann Oncol 2011;22:559-66.
23. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, et al. Effi cacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard fi rst-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial. Lancet 2011; 377:1846-54.
24. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: A phase II consortium study. J Clin Oncol 2010;28:3491-7.
25. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-80.
26. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360: 563-72.
27. Punt CJ, Tol J. More is less - combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol 2009;6: 731-3.
28. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: A vascular biologist's view. Thromb Haemost 2007;97:336-42.
29. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M, et al. Plasminogen activation and cancer. Thromb Haemost 2005;93:676-81.
30. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010;11:23-36.
31. Lomholt AF, Hoyer-Hansen G, Nielsen HJ, Christensen IJ. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer. Br J Cancer 2009;101:992-7.
32. Almasi CE, Hoyer-Hansen G, Christensen IJ, Pappot H. Prognostic signifi cance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer. APMIS 2009;117:755-61.
33. Rasch MG, Lund IK, Almasi CE, Hoyer-Hansen G. Intact and cleaved uPAR forms: Diagnostic and prognostic value in cancer. Front Biosci 2008;13:6752-62.
34. Henic E, Borgfeldt C, Christensen IJ, Casslen B, Hoyer- Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008;14:5785-93.
35. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, et al. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008;68:521-9.
36. Hudelist G, Kostler WJ, Gschwantler-Kaulich D, Czerwenka K, Kubista E, Muller R, et al. Serum EGFR levels and effi - cacy of trastuzumab-based therapy in patients with metastatic breast cancer. Eur J Cancer 2006;42:186-92.
37. Perez-Torres M, Valle BL, Maihle NJ, Negron-Vega L, Nieves- Alicea R, Cora EM. Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. Exp Cell Res 2008;314:2907-18.